Rhodes Pharmaceuticals, L.P.

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Rhodes Pharmaceuticals, L.P. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed later-stage tilt top decile by trial count

Rhodes Pharmaceuticals, L.P.: 10 sponsored US clinical trials, none currently recruiting.

Rhodes Pharmaceuticals, L.P. sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 9 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is ADHD, with 2 trials.

Top-decile sponsor footprint

Rhodes Pharmaceuticals, L.P. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 4

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

NCT02470234
COMPLETED Phase 4

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
COMPLETED Phase 3

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

NCT02555150
COMPLETED Phase 3

PRC-063 in an ADULT Workplace Environment

NCT02225639
COMPLETED Phase 3

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

NCT02168127
COMPLETED Phase 3

PRC-063 in Adolescent ADHD

NCT02139111
COMPLETED Phase 3

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124
COMPLETED Phase 1

Safety and Efficacy of PG101 for Dry Eye Syndrome

NCT02078661
COMPLETED Phase 3

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
COMPLETED Phase 3

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

NCT01239030

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 7
Phase 4 2

Therapeutic Areas

ADHD 2
Attention Deficit Hyperactivity Disorder (ADHD) 1
Attention Deficit Hyperactivity Disorder 1

How the Rhodes Pharmaceuticals, L.P. archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 9 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: ADHD (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Rhodes Pharmaceuticals, L.P.: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Rhodes Pharmaceuticals, L.P. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Rhodes Pharmaceuticals, L.P.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Rhodes Pharmaceuticals, L.P. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rhodes Pharmaceuticals, L.P. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rhodes Pharmaceuticals, L.P. page

10 registered trials is a research-attention snapshot, not an endorsement of Rhodes Pharmaceuticals, L.P. or any single study.

  • None of Rhodes Pharmaceuticals, L.P.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • ADHD is the condition Rhodes Pharmaceuticals, L.P. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See ADHD trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rhodes Pharmaceuticals, L.P. pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.